People In Brief
Merck names Frazier president: Merck, in an expected move, appoints the current head of its Global Human Health business, Ken Frazier, as president of the firm. Frazier moves to the spot after three years in the Global Human Health post and as Merck's general counsel for eight years prior to that, the firm said April 28. Adam Schechter, current U.S. head for Global Human Health, will succeed Frazier as global president. Current Merck President Dick Clark will remain as CEO and chairman; both Schecter and Frazier are seen as potential successors to Clark. Merck in February appointed former Johnson & Johnson executive Bridgette Heller as executive VP and president of its consumer health care division. Whitehouse Station, N.J.-based Merck acquired the division as part of its November 2009 merger with Schering-Plough (1"The Tan Sheet" Feb. 22, 2010)
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
All RSV vaccines with US FDA approval for high-risk younger adult patients will be incorporated in US CDC’s Advisory Committee for Immunization Practices recommendations. Merck’s infant RSV antibody is on track for a June vote
Wide-ranging executive order to lower drug prices also hints at changes in upcoming guidance on the Medicare price negotiation program but few other potentially impactful near-term actions.
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.